Insights from natural infection-derived immunity to cholera instruct vaccine efforts.

Center for Vaccine Development, Department of Pediatrics and Medicine, University of Maryland, School of Medicine, Baltimore, Maryland, USA.
Clinical and vaccine Immunology: CVI (Impact Factor: 2.37). 09/2012; 19(11):1707-11. DOI: 10.1128/CVI.00543-12
Source: PubMed

ABSTRACT Diarrhea caused by Vibrio cholerae O1 (and occasionally O139) remains a notable disease burden in much of the developing world, affecting several million individuals and leaving an estimated toll of > 100,000 deaths annually (1).…

1 Follower
  • [Show abstract] [Hide abstract]
    ABSTRACT: 2D6 is a dimeric monoclonal immunoglobulin A (IgA) specific for the non-reducing terminal residue of Ogawa O-polysaccharide (OPS) of Vibrio cholerae. It was previously demonstrated that 2D6 IgA is sufficient to passively protect suckling mice from oral challenge with virulent V. cholerae O395. In this study, we sought to define the mechanism by which 2D6 IgA antibody protects the intestinal epithelium from V. cholerae infection. In a mouse ligated ileal loop assay, 2D6 IgA promoted V. cholerae agglutination in the intestinal lumen and limited the ability of the bacteria to associate with the epithelium, particularly within the crypt regions. In vitro fluorescence digital video microscopy analysis of antibody-treated V. cholerae in liquid medium revealed that 2D6 IgA not only induced the rapid (5-10 min) onset of agglutination, but was an equally potent inhibitor of bacterial motility. Scanning electron microscopy showed that 2D6 IgA promoted flagellum-flagellum cross-linking, as well as flagella entanglement with bacterial bodies, suggesting that motility arrest may be a consequence of flagella tethering. However, monovalent 2D6 Fab fragments also inhibited V. cholerae motility, demonstrating that antibody-mediated agglutination and motility arrest are separate phenomena. While 2D6 IgA is neither bactericidal nor bacteriostatic, exposure of V. cholerae to 2D6 IgA (or Fab fragments) resulted in a five-fold increase in surface-associated blebs, as well an onset of a wrinkled surface morphotype. We propose that protective immunity conferred by 2D6 IgA is the result of multifactorial effects on V. cholerae, including agglutination, motility arrest and possibly outer membrane stress. Copyright © 2015, American Society for Microbiology. All Rights Reserved.
    Infection and Immunity 02/2015; 83(4). DOI:10.1128/IAI.02856-14 · 4.16 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Vibrio cholerae expresses two primary virulence factors, cholera toxin (CT) and the toxin-coregulated pilus (TCP). CT causes profuse watery diarrhea, and TCP (composed of repeating copies of the major pilin TcpA) is required for intestinal colonization by V. cholerae. Antibodies to CT or TcpA can protect against cholera in animal models. We developed a TcpA holotoxin-like chimera (TcpA-A2-CTB) to elicit both anti-TcpA and anti-CTB antibodies and evaluated its immunogenicity and protective efficacy in the infant mouse model of cholera. Adult female CD-1 mice were immunized intraperitoneally three times with the TcpA-A2-CTB chimera and compared with similar groups immunized with a TcpA+CTB mixture, TcpA alone, TcpA with Salmonella typhimurium flagellin subunit FliC as adjuvant, or CTB alone. Blood and fecal samples were analyzed for antigen-specific IgG or IgA, respectively, using quantitative ELISA. Immunized females were mated; their reared offspring were challenged orogastrically with 10 or 20 LD50 of V. cholerae El Tor N16961; and vaccine efficacy was assessed by survival of the challenged pups at 48 hrs. All pups from dams immunized with the TcpA-A2-CTB chimera or the TcpA+CTB mixture survived at both challenge doses. In contrast, no pups from dams immunized with TcpA+FliC or CTB alone survived at the 20 LD50 challenge dose, although the anti-TcpA or anti-CTB antibody level elicited by these immunizations was comparable to the corresponding antibody level achieved by immunization with TcpA-A2-CTB or TcpA+CTB. Taken together, these findings comprise strong preliminary evidence for synergistic action between anti-TcpA and anti-CTB antibodies in protecting mice against cholera. Weight loss analysis showed that only immunization of dams with TcpA-A2-CTB chimera or TcpA+CTB mixture protected their pups against excess weight loss from severe diarrhea. These data support the concept of including both TcpA and CTB as immunogens in development of an effective multivalent subunit vaccine against V. cholerae.
    PLoS Neglected Tropical Diseases 12/2014; 8(12):e3356. DOI:10.1371/journal.pntd.0003356 · 4.49 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Two cholera vaccines, sold as Shanchol and Dukoral, are currently available. This review presents a critical analysis of protective efficacies of these vaccines. Children under 5 are very vulnerable to the disease, and account for the highest incidence of cholera cases and more than half of the mortality. Both Shanchol and Dukoral are spaced two dose oral vaccines comprising large numbers of killed cholera bacteria. The former contains Vibrio cholerae O1 and O139 cells, and the latter contains V. cholerae O1 cells with the recombinant B subunit of cholera toxin. In a field trial in Kolkata (India), Shanchol, the preferred vaccine, offered protection of 45% in all age groups and only 17% in children under 5 during the first year of surveillance. In a field trial in Peru, two spaced doses of Dukoral offered negative protection in children under 5 and little protection (15%) in vaccinees above 6 during the first year of surveillance. Little is known on Dukoral's long term protective efficacy. Both the vaccines have questionable composition, using V. cholerae O1 strains isolated in 1947 that have been inactivated by heat and formalin treatment which may denature protein . Immunological studies revealed Dukoral's reduced and short-lived efficacy, as measured by several immunological endpoints. Various factors such as necessity for multiple doses, poor protection in children under 5, requirement of cold chain, production cost and complex logistics in vaccine delivery greatly reduce the suitability of either of these vaccines for endemic or epidemic cholera control in resource poor settings.
    Clinical and vaccine Immunology: CVI 07/2014; 21(9). DOI:10.1128/CVI.00378-14 · 2.37 Impact Factor


Available from